Previous 10 | Next 10 |
JuSun/iStock via Getty Images NeuroBo Pharmaceuticals ([[NRBO]] +31.8%) is on course to witness its biggest one-day gain in more than a year today. Last week, the company announced an upcoming Special Meeting scheduled to seek stockholder approval for the issuance of common stock. The of...
NeuroBo Pharmaceuticals (NRBO): Q1 GAAP EPS of -$0.15 beats by $0.01.Cash and Cash Equivalents were $13MPress Release For further details see: NeuroBo Pharmaceuticals EPS beats by $0.01
NeuroBo Pharmaceuticals Reports First Quarter 2021 Financial Results PR Newswire BOSTON , May 17, 2021 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on developing and commercializing multimodal di...
NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded at a new 52-week low today of $3.33. Approximately 1.1 million shares have changed hands today, as compared to an average 30-day volume of 213,000 shares. NeuroBo Pharmaceuticals Inc is a clinical-stage biopharmaceutical company. It is en...
Shares of NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded today at $3.20, breaking its 52-week low. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares. Potential upside of 65.6% exists for NeuroBo Pharmaceuticals...
Gainers: Purple Biotech (PPBT) +9%, NeuroBo Pharmaceuticals (NRBO) +7%, Obalon Therapeutics (OBLN) +7%, Dare Bioscience (DARE) +4%, Hoth Therapeutics (HOTH) +2%.Losers: Syndax Pharmaceuticals (SNDX) -28%, Zai Lab (ZLAB) -13%, KalVist...
NeuroBo Pharmaceuticals Inc. (NASDAQ:NRBO) traded at a new 52-week low today of $3.17. So far today approximately 1.1 million shares have been exchanged, as compared to an average 30-day volume of 213,000 shares. NeuroBo Pharmaceuticals Inc. share prices have moved between a 52-week high...
NeuroBo Pharmaceuticals Reports Full Year 2020 Financial Results and Provides Corporate Strategic Update Acquisition of ANA Therapeutics provides late-stage COVID-19 clinical development program with numerous key inflection points in 2021 PR Newswire BOSTON , A...
Penny stocks are well-known for their high risk and potential for high reward. Because of that, many advisors suggest that this type of investment only take a small portion of your overall holdings. Some top financial firms have a rule of thumb that 10% or less is a good benchmark for high-...
NeuroBo Pharmaceuticals (NRBO) perks up 6% premarket after receiving approval of an amendment to its Contingent Value Rights ((CVR)) agreement from a majority of CVR holders. The CVRs were distributed to the holders of Gemphire Therapeutics (GEMP) common stock on December 30, 2019, ...
News, Short Squeeze, Breakout and More Instantly...
NeuroBo Pharmaceuticals Inc. Company Name:
NRBO Stock Symbol:
NASDAQ Market:
NeuroBo Pharmaceuticals Inc. Website:
NeuroBo Pharmaceuticals Announces Exclusive License Agreement with MThera Pharma for NB-01 PR Newswire CAMBRIDGE, Mass. , July 30, 2024 /PRNewswire/ -- NeuroBo Pharmaceuticals, Inc. (Nasdaq: NRBO), a clinical-stage biotechnology company focused on the transfo...
NeuroBo Pharmaceuticals Doses First Patient in the MAD Part 2 of Its Phase 1 Clinical Trial Evaluating DA-1726 for the Treatment of Obesity PR Newswire Top-Line Data Readout From the Single Ascending Dose Part 1 Expected in the Third Quarter of 2024, and From the Multiple Asce...
NeuroBo Pharmaceuticals Announces the Closing of up to $70 Million Concurrent Private Placement and Registered Direct Offering Priced At-the-Market Under Nasdaq Rules PR Newswire $20 million upfront with up to an additional $50 million of aggregate gross proceeds upon ...